RIPK3 and melanoma: In the B16 melanoma model, intratumoral application of low-dose AZA without direct cytotoxic effects did increase transcriptional activity of both Ripk3 and Mlkl in tumor cells in vivo (figure 5A and online supplemental figure S6D).